Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial.
By D. Harper, E. Franco, C. Wheeler, A. Moscicki, B. Romanowski, C. Roteli-Martins, D. Jenkins, A. Schuind, S. A. Costa Clemens, G. Dubin. The Lancet, 2006
1,626 citations recorded by the source corpus.
Subfields: Epidemiology, Microbiology, Otorhinolaryngology
View Paper: https://www.semanticscholar.org/paper/ead8931b56deb09d4b7087c9808d2b85b8b69b83
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Epidemiology
Citations in the corpus
- Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial. (2007, background): “Viruslike particle–based vaccines have been shown to provide near complete type-specific protection against infection with HPV types included in the vaccine in the initial years following vaccination.(2,3,6) Preliminary evidence suggests that at least 1 of the vaccines (the bivalent HPV-16/18 cervic”
- High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up (2006, background): “Recently, a bivalent HPV 16/18 vaccine showed high efficacy against persistent HPV 16 or 18 infections through 4.5 years (Harper et al, 2006).”
- Global cancer statistics (2011, background): “even vaccinated girls should begin screening when they reach the recommended screening age since the vaccines do not provide protection for the 30% of chronic infections by HPV types other than HPV 16, 18, 6 and 11 that cause cervical cancer.(94,95)”